8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 13, 2026·SEC
Azitra, Inc.(AZTR)Earnings, Financials & Key Ratios
AZTR•AMEX
$0.16
Price updated Jun 27, 2026
AboutAzitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.Show more
- Revenue$0-100.0%
- EBITDA-$11M+99.9%
- Net Income-$11M-22.2%
- EPS (Diluted)-2.25-532.2%
- ROE-0.58%+99.7%
AZTR Price & Volume
Azitra, Inc. (AZTR) stock price & volume — 10-year historical chart
Loading chart...
Extreme Financial Anomalies Obscure Clinical Development Path
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
"Azitra remains a pre-commercial biotechnology entity characterized by persistent operational losses and significant data integrity concerns that complicate fundamental valuation. The company's reliance on external capital to fund R&D is evidenced by a cumulative retained earnings deficit of $72.4 billion as of 2026Q1. Investors should exercise extreme caution given the lack of recurring revenue and the presence of erratic, multi-billion dollar financial reporting outliers that deviate from standard micro-cap profiles."
Verdict Logic
the company's financial statements contain material reporting distortions, such as the $2.5 billion cash outflow in 2026Q1, which prevents a reliable assessment of the firm's actual liquidity and operational runway.
AZTR Growth Metrics
Azitra, Inc. (AZTR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-29.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-376.82%
Return on Capital
10 Years-46359.42%
5 Years-46359.42%
3 Years-77186.29%
Last Year-0.55%
AZTR Recent Earnings
Azitra, Inc. (AZTR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (57%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.25-2400.0%
$0.01
Rev
—
—
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$1.15-210.8%
$0.37
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.67+15.2%
$0.79
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$1.20+14.3%
$1.40
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.25vs $0.01-2400.0% | — |
| Q2 2026 | Mar 2, 2026 | $1.15vs $0.37-210.8% | — |
| Q4 2025 | Nov 12, 2025 | $0.67vs $0.79+15.2% | — |
| Q3 2025 | Aug 11, 2025 | $1.20vs $1.40+14.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Azitra, Inc. (AZTR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.16 | $1.74M | -0.07 | -100% | — | -0.58% | — | |
| $123.77 | $6.21B | -263.34 | 54.74% | -194.97% | -289.33% | — | |
| $9.29 | $723.79M | -4.67 | — | — | -74.45% | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — | |
| $0.94 | $5.25M | -0.06 | — | — | — | — | |
| $21.31 | $1.88B | -6.48 | 627.84% | -112.01% | -256.66% | — |
Compare AZTR vs Peers
Azitra, Inc. (AZTR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AZTR SEC Filings & Documents
Azitra, Inc. (AZTR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AZTR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AZTR Frequently Asked Questions
Azitra, Inc. (AZTR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Azitra, Inc. growing?
Azitra, Inc. (AZTR) saw revenue decline by 100.0% over the past year.
Is AZTR profitable?
Azitra, Inc. (AZTR) reported a net loss of $11.8M for fiscal year 2025.
Dividend & Returns
What is AZTR's return on equity?
Azitra, Inc. (AZTR) has a return on equity (ROE) of -0.6%. Negative ROE indicates the company is unprofitable.
What is Azitra, Inc.'s free cash flow?
Azitra, Inc. (AZTR) had negative free cash flow of $2.50B in fiscal year 2025, likely due to heavy capital investments.